JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JCM.01388-06v1
44/11/3883    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, G.
Right arrow Articles by Bruckner, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, G.
Right arrow Articles by Bruckner, D. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2006, p. 3883-3886, Vol. 44, No. 11
0095-1137/06/$08.00+0     doi:10.1128/JCM.01388-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year Period{triangledown}

Guiqing Wang,* Janet F. Hindler, Kevin W. Ward, and David A. Bruckner

Clinical Microbiology Laboratory, Department of Pathology and Laboratory Medicine, UCLA Medical Center, Los Angeles, California 90095-1713

Received 6 July 2006/ Returned for modification 12 July 2006/ Accepted 22 August 2006

Staphylococcus aureus is one of the most commonly isolated organisms in nosocomial infections. While the prevalence of methicillin-resistant S. aureus (MRSA) continues to increase worldwide, there is concern about an increase in vancomycin MICs among S. aureus strains. The prevalence of MRSA and vancomycin MIC trends in S. aureus from patients in a university hospital were analyzed. Clinical Laboratory Standards Institute (CLSI, formerly NCCLS) reference broth microdilution MIC testing was performed on all clinically relevant S. aureus isolates from January 2000 through December 2004. A total of 6,003 S. aureus isolates were analyzed. No vancomycin-resistant S. aureus isolates were detected. One MRSA isolate had a vancomycin MIC of 8 µg/ml and was confirmed as vancomycin-intermediate S. aureus. Among the 6,002 remaining isolates, a shift in vancomycin MICs from ≤0.5 to 1.0 µg/ml was observed during the 5-year period. The percentage of S. aureus isolates with a vancomycin MIC of 1 µg/ml in 2004 was significantly higher than the percentage of isolates in 2000 (70.4% versus 19.9%; P < 0.01). This vancomycin MIC shift was more notable in methicillin-susceptible S. aureus. Our 5 years of routine testing of clinical isolates using the CLSI reference broth microdilution MIC method demonstrated a tendency toward decreasing susceptibility to vancomycin in S. aureus.

* Corresponding author. Mailing address: Clinical Microbiology Laboratory, Medical Center of the University of California at Los Angeles, 10833 LeConte Avenue, Los Angeles, CA 90095-1713. Phone: (310) 794-2766. Fax: (310) 794-2765. E-mail: gw2004{at}gmail.com.

{triangledown} Published ahead of print on 6 September 2006.

Journal of Clinical Microbiology, November 2006, p. 3883-3886, Vol. 44, No. 11
0095-1137/06/$08.00+0     doi:10.1128/JCM.01388-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.